User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are injectable glucose-lowering medications approved for the treatment of adult patients with type 2 diabetes mellitus (T2DM). This article provides practical information to guide primary care physicians on the use of GLP-1RAs in patients with T2DM. Two short-acting (once- or twice-daily administration; exenatide and liraglutide) and three long-acting (weekly administration; albiglutide, dulaglutide and exenatide) GLP-1RAs are currently approved in the US. These drugs provide levels of GLP-1 receptor agonism many times that of endogenous GLP-1. The GLP-1RAs have been shown to significantly improve glycemic parameters and reduce body weight. These agents work by activating GLP-1 receptors in the pancreas, which leads to enhanced insulin release and reduced glucagon release-responses that are both glucose-dependent-with a consequent low risk for hypoglycemia. Effects on GLP-1 receptors in the CNS and the gastrointestinal tract cause reduced appetite and delayed glucose absorption due to slower gastric emptying. The most common adverse effects are gastrointestinal, which are transient and less common with the long-acting drugs. GLP-1RAs are recommended as second-line therapy in combination with metformin, sulfonylureas, thiazolidinediones or basal insulin, providing a means of enhancing glucose control while offsetting the weight gain associated with insulin and some oral agents. GLP-1RAs represent a useful tool that the primary care physician can use to help patients with T2DM achieve their therapeutic goals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the gastrointestinal tract, GLP-1RAs can delay gastric emptying and glucose absorption, promoting greater satiety between meals [10].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [10]
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 7×
“GLP-1RAs also increase glucose-induced insulin biosynthesis at the translational level, thus maintaining b-cell insulin stores and secretory capacity [6].”
BackgroundInfluentialInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Guidelines from the ADA and EASD recommend metformin as the preferred initial therapy unless contraindicated, with the addition of a sulfonylurea, thiazolidinedione (TZD), DPP-4 inhibitor, SGLT-2 inhibitor, GLP-1RA or basal insulin if the glycated hemoglobin (A1C) target is not achieved after 3 months with the maximum…”
BackgroundDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“In addition to enhancing the amount of insulin released, GLP-1 infusion also normalizes the pattern of insulin release by restoring first-phase insulin response in patients with T2DM [12].”
BackgroundEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“Pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in postmarketing surveillance reports for patients receiving GLP-1RAs [49].”
BackgroundNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 1×
“Approximately 50 years ago, it was reported that an oral glucose load evokes a greater insulin response than an equivalent intravenous glucose load [5].”
BackgroundKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 1×
“Notably, a post hoc analysis of patients treated with exenatide for ‡ 3 years in one of three studies showed that, while most patients (68%) achieved reductions in both A1C and body weight, 10% of patients had reductions in A1C despite increased body weight [43].”
MethodBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“Monitoring of serum calcitonin in clinical trials with GLP-1RAs has shown no such increase in humans [53].”
Background
Research works printed but not linked: 12
- Centers for Disease Control and Prevention, 2014, National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014
- TRULICITY (dulaglutide) injection, for subcutaneous use, 2015, US prescribing information
- TANZEUM (albiglutide) for injection, for subcutaneous use, 2015, US prescribing information
- BYETTA (exenatide) injection, 2015, US prescribing information
- VICTOZA (liraglutide [rDNA origin] injection), 2015, US prescribing information
- BYDUREON (exenatide extended-release for injectable suspension), 2015, US prescribing information
- Jimenez-Solem E, 2010, Curr Opin Mol Ther, 12, 790
- Kapitza C, 2012, Diabetologia, 55, S341
- Abdul-Ghani MA, 2013, J Endocrinol Invest, 36, 168
- Rosenwasser RF, 2013, Diabetes Metab Syndr Obes, 6, 453
- Saxenda (liraglutide [rDNA origin] injection), 2015, US prescribing information
- Koro CE, 2013, Diabetes, 62, A415
Cited by
Frías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30267-4 · Cited by 398
Alam, S., Sarker, M. M. R., Sultana, T. N., Chowdhury, M. N. R., Rashid, M. A., Chaity, N. I., Zhao, C., Xiao, J., Hafez, E. E., Khan, S. A., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.800714 · Cited by 349
Wong, H. J., Sim, B., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y. Q., Sattar, N., Dalakoti, M., et al. (2025) · Diabetes Care · doi:10.2337/dc24-1678 · Cited by 208
Ansari, H. U. H., Qazi, S. U., Sajid, F., Altaf, Z., Ghazanfar, S., Naveed, N., Ashfaq, A. S., Siddiqui, A. H., Iqbal, H., & Qazi, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.11.007 · Cited by 112
Role of diet and exercise in aging, Alzheimer’s disease, and other chronic diseases
Khemka, S., Reddy, A., Garcia, R. I., Jacobs, M., Reddy, R. P., Roghani, A. K., Pattoor, V., Basu, T., Sehar, U., & Reddy, P. H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102091 · Cited by 88
Metadata
- Authors
- Shaefer, C. F., Kushner, P., & Aguilar, R.
- Affiliations
- Augusta University (US)
- Diabetes Canada (CA)
- Corresponding author
- Shaefer, Charles F
- ORCID
- Kushner, Pamela
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2015-09-15
- Volume
- 127
- Issue
- 8
- Pages
- 818-826
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W1863540633
- Cited by
- 128
- References
- 56
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 35 · 2023: 23 · 2022: 13 · 2021: 1 · 2020: 2 · 2018: 3 · 2017: 3 · 2016: 1
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Postgraduate Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, exenatide, liraglutide, albiglutide, dulaglutide, mechanism of action, glycemic control, weight loss, hypoglycemia risk, gastrointestinal adverse effects, primary care management
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Blood Glucose, Energy Intake, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Gastric Emptying, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Pancreas, Primary Health Care, Weight Loss, Glucagon-Like Peptide 1, Incretins, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. https://app.cochat.ai/papers/10.1080/00325481.2015.1090295
- The paper
- Shaefer, C. F., Kushner, P., & Aguilar, R. (2015). User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgraduate Medicine. https://doi.org/10.1080/00325481.2015.1090295
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.